New-leadership

Leadership

<span data-metadata=""><span data-buffer="">Leadership

Robert Mitchell | Chief Executive Officer

Founder RDM Enterprises. CEO N8 Medical, Cora Therapeutics Nellix Inc, Millimed Holdings, President Endologix, COO Angio Dynamics, SVP Cook Medical, EVP Align Technologies.

Carl Genberg, B.Sc. J.D. | Chief Development and Science Officer

Entrepreneur, Scientist, Regulatory Specialist, Co-Inventor. Co-founder of Goldman Sachs funded medical device company, achieved a $1 billion market cap at its peak.

Olga Yanvoskaya | International Sales & Marketing

Former executive with Covidien/Medtronic.

Glenn Brunner | Quality Assurance

President, CEO Medical Device Engineer of large to early-stage medical device companies Medex (Smiths Medical), Opticon Medical, (Bard BD), Wiseology LLC.

Chief Executive Officer | In Transition

In Transition

Carl Genberg, B.Sc. J.D. | Chief Development and Science Officer

Entrepreneur, Scientist, Regulatory Specialist, Co-Inventor. Co-founder of Goldman Sachs funded medical device company, achieved a $1 billion market cap at its peak.

Olga Yanvoskaya | International Sales & Marketing

Former executive with Covidien/Medtronic.

Glenn Brunner | Quality Assurance

President, CEO Medical Device Engineer of large to early-stage medical device companies Medex (Smiths Medical), Opticon Medical, (Bard BD), Wiseology LLC.

Board of Directors

Jay Golding | Chairman

Founder, CEO Hi-Port Industries, Falcon Seaboard, Golding Brothers Partners. Director of Benchmark Hospitality and other private companies

Robert Mitchell | Director/Chief Executive Officer

Founder RDM Enterprises. CEO N8 Medical, Cora Therapeutics, Nellix Inc, Millimed Holdings, President Endologix (ELGX), COO Angio Dynamics (ANGO), SVP Cook Medical, EVP Align Technology (ALGN)

Jay Golding | Chairman

Founder, CEO Hi-Port Industries, Falcon Seaboard, Golding Brothers Partners. Director of Benchmark Hospitality and other private companies

Raymond K. Houck | Director

Current CEO of Aclipse Therapeutics, Former CEO & Co-Founder of Thar Pharmaceuticals, Automated Cell, and Suprex Corporation

Carl Genberg, JD | Director/Chief Development and Science Officer

Entrepreneur, Scientist, Regulatory Specialist, Inventor. Co-founder of Goldman Sachs funded medical device company, achieved $1 Billion market cap at its peak.

Peter Allen | Director

Industry veteran led Becton Dickinson IV catheter business, EVP for Vizient, the worlds largest GPO.

Henry Haimsohn | Director

Served in a number of positions at Handyman of California a subsidiary of Edison Brothers Stores. Founded the Pace Membership Warehouse as its Chairman and CEO.

Shawn Langer | Director

Brings over two decades of healthcare industry experience, and served as a Senior Partner at McKinsey & Company as the leader of its Healthcare Private Equity Group.

Chief Advisors

Chief Advisors

Paul Savage, PhD | Science and Chemistry

Professor of Chemistry BYU, Inventor of Ceragenin class of compounds. Author of >175 peer reviewed journal articles.

Ronald Bracken | Coatings and Operations

Industry veteran, Former VP of R&D at CR Bard leading antimicrobial device coatings.

Michael Niederman | Critical Care Medicine

Associate Chief & Clinical Dir of Pulmonary and Critical Care Medicine at Weill Cornell. Wrote guidelines for treatment of Nosocomial Pneumonia.

David Perlin, PhD | Medical Research

Highly accomplished medical researcher. Chief Scientific Officer and SVP for Hackensack Meridian Health Center for discover and innovation

Jorge Hildago, M.D. | Critical Care Medicine

Professor of Critical Care at Karl Heuser Memorial in Belize. Secretary General of World Federation of Societies of Critical Care and Intensive Care Medicine.

Lisa Dwyer | Regulatory Strategy

Partner at King & Spalding. Specialization in FDA and Life Science. 20 years developing regulatory and legislative solutions.

Don Boyer | Canadian Regulatory

30 years experience as an expert regulatory consultant to the health products industry. Former head of Health Canada medical device department.

John Doucet | Regulatory Strategy

Former US Food and Drug Administration (FDA) Policy Lead, for the Breakthrough Device Program.

Matthew Reed, PhD | Toxicology with Expertise in Cystic Fibrosis

Dr. Reed is a pharmacologist, board certified toxicologist, past ABT Board Member, and Fellow of the Academy of Toxicology Sciences (ATS). He has a close relationship with the Cystic Fibrosis Therapeutics Foundation.

Michelle Higgin, PhD | Program Leadership

Aggressive program management, preclinical pharmacology, nonclinical, regulatory, and early phase clinical trials. Michelle has opened 40+ INDs/IMPDs/CTAs/NDAs in US, Europe, and Australia.

Dale Christensen, PhD | Clinical Development

Experience managing pre-clinical discovery and pharmacology efforts across respiratory, inflammation, CNS, anti-infective, and oncology indications.

Tom Richardson, PhD | Science and Chemistry

Over 30 years of experience in formulation, drug delivery technologies and drug product manufacturing.

Jeffrey Wang, M.D. | Toxicology with Expertise in Cystic Fibrosis

Professor of Orthopedic Surgery and Neurosurgery at USC. Chief of USC Orthopedic Spine Services, Keck School of Medicine.

Michael John | Regulatory Strategy

Chief of the Interventional Cardiology Devices Branch in the Division of Cardiovascular Devices at the US Food and Drug Administration.

Georg Wieselthaler, M.D. | SBIR Consultant – Cardiology KOL

UCSF’s director and surgical chief of Cardiac Transplantation and Mechanical Circulatory Support.

Prabir Roy-Chaudhury, M.D. | SBIR Consultant – Kidney KOL

Professor of Medicine UNC Kidney Center, Division of Nephology and Hypertension. Main research in uremic vascular biology.

Contact us

Lets Get in Touch!

Follow now

mynewform

Basic contact form

N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.